Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Clin Pharmacol Ther. 2018 May 15;104(6):1175–1181. doi: 10.1002/cpt.1093

Figure 3.

Figure 3

Number of regulatory applications (INDs) with FDA-generated documents in the DARRTS database that referenced FDA reviewer recommendations for the use of KIM-1 vs sponsor’s planned or actual use of KIM-1 as a drug development tool.